{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:15:52Z","timestamp":1753888552075,"version":"3.41.2"},"reference-count":13,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz. J. Pharm. Sci."],"DOI":"10.1590\/s2175-97902023e21480","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T15:28:43Z","timestamp":1681486123000},"source":"Crossref","is-referenced-by-count":0,"title":["Development of a validated stability-indicating HPLC- DAD method for dasabuvir and the characterization of its degradation products using LC-QToF-MS\/MS"],"prefix":"10.1590","volume":"59","author":[{"given":"Allan Michael","family":"Junkert","sequence":"first","affiliation":[{"name":"Federal University of Paran\u00e1,  Brazil"}]},{"given":"Breno Maur\u00edcio","family":"Marson","sequence":"additional","affiliation":[{"name":"Federal University of Paran\u00e1,  Brazil"}]},{"given":"Mariana Millan","family":"Fachi","sequence":"additional","affiliation":[{"name":"Federal University of Paran\u00e1,  Brazil"}]},{"given":"Raquel de Oliveira","family":"Vilhena","sequence":"additional","affiliation":[{"name":"Federal University of Paran\u00e1,  Brazil"}]},{"given":"Beatriz","family":"B\u00f6ger","sequence":"additional","affiliation":[{"name":"Federal University of Paran\u00e1,  Brazil"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-4363","authenticated-orcid":false,"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[{"name":"Federal University of Paran\u00e1,  Brazil"}]}],"member":"530","published-online":{"date-parts":[[2023]]},"reference":[{"year":"2019","series-title":"Viekira Pak\u00ae (Ombitasvir, paritaprevir and ritonavir copackaged with dasabuvir) Highlights of prescribing information","key":"ref1"},{"year":"2017","series-title":"Resolu\u00e7\u00e3o da Diretoria Colegiada - RDC N\u00ba 166. Valida\u00e7\u00e3o de m\u00e9todos anal\u00edticos","key":"ref2"},{"year":"2019","series-title":"Resolu\u00e7\u00e3o da Diretoria Colegiada - RDC N\u00ba 318. Crit\u00e9rios para a realiza\u00e7\u00e3o de Estudos de Estabilidade de insumos farmac\u00eauticos ativos e medicamentos","key":"ref3"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-016-0232-6","article-title":"Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD","volume":"11","author":"Al-Zoman NZ","year":"2017","journal-title":"Chem Cent J"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC-MS\/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir\/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo A","year":"2016","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0731-7085(02)00047-X","article-title":"Development of validated stability-indicating assay methods - Critical review","volume":"28","author":"Bakshi M","year":"2002","journal-title":"J Pharm Biomed Anal"},{"year":"2015","series-title":"Exviera\u00ae (EMEA\/ H\/C\/003837)","key":"ref7"},{"year":"2003","key":"ref8"},{"year":"1996","key":"ref9"},{"year":"1994","key":"ref10"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.trac.2013.05.008","article-title":"Practical and regulatory considerations for stability-indicating methods for the assay of bulk drugs and drug formulations","volume":"49","author":"Maggio RM","year":"2013","journal-title":"TrAC Trends Anal Chem"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchromb.2017.03.020","article-title":"Ultra-performance liquid chromatography tandem mass spectrometry for determination of direct acting antiviral drugs in human liver fine needle aspirates","volume":"1052","author":"Ocque AJ","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cpdd.246","article-title":"Drug-drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir\/ritonavir and ombitasvir with and without dasabuvir","volume":"5","author":"Polepally AR","year":"2016","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Brazilian Journal of Pharmaceutical Sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S1984-82502023000100316&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T15:28:50Z","timestamp":1681486130000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1984-82502023000100316&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":13,"alternative-id":["S1984-82502023000100316"],"URL":"https:\/\/doi.org\/10.1590\/s2175-97902023e21480","relation":{},"ISSN":["2175-9790"],"issn-type":[{"type":"electronic","value":"2175-9790"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e21480"}}